基于基线血肌酐回推评估的尸体供者急性肾损伤与移植物存活的关系:法国国家CRISTAL登记研究结果
中位随访5.7年发生4458例移植物丢失;与无AKI相比,持续性AKI、不确定AKI/CKD和AKI恢复组移植物失败风险均升高,而用入院或最低血肌酐作基线则不再显示该不良效应。
要点
- 供者持续性AKI与移植物失败风险升高相关(HR 1.24,95%CI 1.13-1.35)。
- 供者不确定AKI/CKD和AKI恢复亦与移植物失败风险升高相关。
- 以入院或最低血肌酐作基线会误分类并导致错误估计。
核心结论
- 按回推基线血肌酐定义,供者持续性AKI、不确定AKI/CKD和AKI恢复均与移植物存活下降相关。
- 以入院首次或采购过程最低血肌酐作为基线会引入误分类偏倚和错误估计。
研究设计与样本
- 观察性队列研究,数据来自法国CRISTAL登记。
- 采用MDRD公式按假设GFR 75mL/min/1.73m2回推基线血肌酐,将供者AKI分为无AKI、不确定AKI/CKD、AKI恢复和持续性AKI。
- 结局为死亡删失的移植物存活,采用针对同一供者配对肾脏的稳健方差估计的多变量Cox模型。
主要发现
- 中位随访5.7年共发生4458例移植物丢失。
- 与无AKI相比,持续性AKI组移植物失败风险升高(HR 1.24,95%CI 1.13-1.35)。
- 不确定AKI/CKD组HR为1.22(95%CI 1.07-1.38),AKI恢复组HR为1.18(95%CI 1.06-1.31)。
- 以入院或采购过程最低血肌酐作基线时,供者AKI的不良效应不再明显。
关键数值与推荐
- 供者AKI分类:无AKI(n=19276)、不确定AKI/CKD(n=1745)、AKI恢复(n=2392)、持续性AKI(n=3373)。
临床怎么用
- 评估尸体供者AKI时应采用回推基线血肌酐,而非入院首次或最低血肌酐。
- 供者持续性AKI、不确定AKI/CKD和AKI恢复均提示移植物存活风险升高,供肾评估和受者随访需考虑。
局限性
- 未测量供者尿量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Deceased donor acute kidney injury (AKI) frequently leads to kidney discards, but its impact on long-term graft survival in kidney transplant recipients remains unclear. We investigated the association between deceased donor AKI assessed using back-estimation of baseline serum creatinine (Scr) and graft survival. STUDY DESIGN: Observational cohort study. SETTING & PARTICIPANTS: Adult patients represented within the French CRISTAL registry who received a single kidney allograft from brain-dead deceased donors between January 2006 and December 2017. EXPOSURE: A back-estimated Scr baseline value was derived for an assumed glomerular filtration rate at 75mL/min/1.73m2, using the MDRD Study equation. A refined classification system for donor AKI was implemented as follows: no AKI, undetermined AKI/chronic kidney disease (CKD), recovery from AKI, and ongoing AKI. OUTCOME: Death-censored graft survival. ANALYTICAL APPROACH: Multivariable Cox models using a robust variance estimator for paired kidneys from the same donor. RESULTS: We classified 26,786 recipients as follows: no AKI (n=19,276); undetermined AKI/CKD (n=1,745); recovery from AKI (n=2,392); and ongoing AKI (n=3,373). We observed 4,458 kidney graft losses during a median follow-up period of 5.7 years. Compared with no AKI, ongoing AKI was associated with an increased risk of graft failure (hazard ratio [HR], 1.24 [95% CI, 1.13-1.35]). The HRs for graft failure in the undetermined AKI/CKD and recovery from AKI groups (1.22 [95% CI, 1.07-1.38] and 1.18 [95% CI, 1.06-1.31], respectively) were similar to those observed in the ongoing AKI group. The adverse effect of deceased donor AKI was no longer evident when relying either on the admission or the lowest Scr throughout the procurement procedure as baseline Scr. LIMITATIONS: No measurement of urine output in donors. CONCLUSIONS: Deceased donor ongoing AKI, undetermined AKI/CKD, and recovery from AKI according to back-estimated baseline Scr are associated with decreased graft survival. The definition of baseline Scr as the first value measured on admission would have led to a misclassification bias and erroneous estimates.
引用
- Lenain R, Prouteau C, Hamroun A, et al. Association Between Deceased Donor Acute Kidney Injury Assessed Using Baseline Serum Creatinine Back-Estimation and Graft Survival: Results From the French National CRISTAL Registry. Am J Kidney Dis. 2021. PMID: 34416353. doi:10.1053/j.ajkd.2021.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。